Alle Storys
Keine Story von Intercell AG mehr verpassen.

Intercell AG

euro adhoc: Intercell AG
Recruitment completed for optimization trial of therapeutic Hepatitis C vaccine

Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
Vienna (Austria), May 3, 2005 - Intercell AG (Vienna Stock Exchange:
ICLL), today announced completion of recruitment in a new clinical
trial of its therapeutic vaccine IC41 against Hepatitis C optimizing
the route and frequency of vaccinations.
The vaccine has been tested in a Phase II clinical trial in
non-responders to Interferon/Ribavarin therapy, a very difficult to
treat group. In this trial an induction of T-cells was observed in a
subset of patients that was concomitant with a transient reduction of
viral load (HCV RNA). The results of the completed Phase I and II
trials were presented on April 14th at the conference of the European
Association for the Study of the Liver (EASL) in Paris.
The current follow up study has been designed to further increase the
T-cell response that is pivotal to fight the infection by optimizing
the route and the frequency of vaccinations. The new study is being
performed at the General Hospital of Vienna, where Intercell´s IC41
Hepatitis C vaccine, is applied to over 50 healthy volunteers by
administering up to 16 vaccinations at weekly intervals. Should
results warrant, the study will be extended to chronic HCV patients
with a less compromised immune system in 2006. The start of Phase III
registration trials is planned for 2008, allowing entry into a market
that is seen at greater EUR 3.5 bn per year in 2011.
Prof. Michael Manns from the Medical University in Hanover states: "I
am convinced that the achieved induction of T-cells in chronic
non-responders patients as shown in Intercell’s Phase II study has
paved the way to the development of a therapeutic vaccine for novel
stand alone and combination treatments". 
Alexander von Gabain, CEO of Intercell, says: "We belong to the few
pioneers working on new treatments against Hepatitis C. Our
therapeutic vaccine in this field of high medical need is latest
state of the art vaccine technology".
About IC41:
IC41 is a fully synthetic vaccine designed for treatment of chronic
HCV patients combining the T-cell adjuvant Poly-L-Arginine with 5
peptides, identified through studies of people with natural immunity
to HCV or successful response towards Interferon/Ribavirin standard
therapy. IC41 has completed Phase I and II trials confirming an
excellent safety profile. IC41 is also being tested in combination
with standard therapy in another Phase II trial. This trial is
expected to be completed in 2006.
About HCV:
HCV is a major cause of chronic liver disease, including cirrhosis
and liver cancer. According to the World Health Organization (WHO),
worldwide, approximately 170 million people are chronic HCV carriers
(3% of the world’s population), including about 10 Million Europeans,
3.9 Million Americans and 2 Million Japanese are infected with HCV,
and 35.000 new infections occur in the US alone each year. The high
unmet medical need is underscored by the fact that each year 8,000 to
10,000 deaths and 1,000 liver transplantations are due to HCV in the
US only. Currently, there is no vaccine against Hepatitis C and the
infection can only be treated with a combination of Interferon and
Ribavirin - a long-term therapy with limited efficacy and significant
side effects. It gives rise to very high annual costs per patient. In
2002, worldwide sales of HCV drugs totalled at around EUR 2.8 bn, and
demand is growing fast. The market is seen to be expanding to EUR 3.5
bn by 2006.
This communication expressly or implicitly contains certain
forward-looking statements concerning Intercell AG and its business.
Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Intercell AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Intercell AG is providing this communication as of this date and does
not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.
The information contained herein is not for publication or
distribution in the United States of America. This press release is
not an offer of securities for sale in the United States. Securities
may not be offered or sold in the United States absent registration
or an exemption from registration under the U.S. Securities Act of
1933, as amended. Any public offering of securities to be made in the
United States will be made by means of a prospectus that may be
obtained from Intercell AG and that will contain detailed information
about the company and management, as well as financial statements.
end of announcement                    euro adhoc 03.05.2005 08:00:45 

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303

Branche: Biotechnology
ISIN: AT0000612601
Börsen: Wiener Börse AG / official market

Weitere Storys: Intercell AG
Weitere Storys: Intercell AG